Podcasts about jama network open

Megan, 36, has lived with T1D since age 4 and now faces lupus too. Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED  or call 888-721-1514 Tandem Mobi  twiist AID System Free Juicebox Community (non Facebook) Type 1 Diabetes Pro Tips - THE PODCAST Juice Cruise 2026 - Come Sail Away Eversense CGM Medtronic Diabetes Drink AG1.com/Juicebox Touched By Type 1 Take the T1DExchange survey Use code JUICEBOX to save 40% at Cozy Earth  Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. Brown et al. Diabetes Care (2021). Sherr et al. Diabetes Care (2022). Pasquel FJ, et al. JAMA Network Open (2025). Single-arm studies comparing 3 months of Omnipod 5 use to standard therapy in 240 people aged 6-70 years and 80 people aged 2-5.9 years with type 1 diabetes and 305 people aged 18-75 years with type 2 diabetes. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!  

 It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: cancer reserach may lead to T1D treatment, GLP-1 oral pill moves forward, Tandem pharmacy moves, Medtronic-Abbott sensor unveield, parents of kids with T1D see income drop, Mannkind submits Afrezza for pediatrics, diabetes scholarships and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Cornell researchers have developed an implant system that can treat type 1 diabetes by supplying extra oxygen to densely packed insulin-secreting cells, without the need for immunosuppression. The system could also potentially provide long-term treatment for a range of chronic diseases. This lab has produced previous implantable devices that have proved effective in controlling blood sugar in diabetic mice, but they can only last so long. "It's the proof of concept. We really proved that oxygenation is important, and oxygenation will support high cell-density capsules," Tempelman said. "The capsules are immune protective and last for a long time without having some kind of fouling of the membrane. The body never likes it when you put a foreign substance in. So that's the engineering in the Ma Lab, to look for materials and coatings for the materials that are immune protective, but also don't invoke excess response from the body because of the material." The next step will be to implant the system in a pig model, and also test it with human stem cells. The researchers are interested in eventually trying to use the system for implanting different cell types in humans for long-term treatment of chronic diseases, according to Tempelman, who is CEO of Persista Bio Inc., a new startup she founded with Ma and Flanders that is licensing these technologies. https://medicalxpress.com/news/2025-08-implant-diabetes-oxygenating-insulin-cells.html XX Mayo Clinic cancer research may be big news for T1D. After identifying a sugar molecule that cancer cells use on their surfaces to hide from the immune system, the researchers have found the same molecule may eventually help in the treatment of type 1. Cancer cells use a variety of methods to evade immune response, including coating themselves in a sugar molecule known as sialic acid. The researchers found in a preclinical model of type 1 diabetes that it's possible to dress up beta cells with the same sugar molecule, enabling the immune system to tolerate the cells. The findings show that it's possible to engineer beta cells that do not prompt an immune response   In the preclinical models, the team found that the engineered cells were 90% effective in preventing the development of type 1 diabetes. The beta cells that are typically destroyed by the immune system in type 1 diabetes were preserved.     https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-researchers-find-sugar-coating-cells-can-protect-those-typically-destroyed-in-type-1-diabetes/ XX A daily pill may be as effective in lowering blood sugar and aiding weight loss in people with Type 2 diabetes as the popular injectable drugs Mounjaro and Ozempic, according to results of a clinical trial announced by Eli Lilly on Thursday morning.   The drug, orforglipron, is a GLP-1, a class of drugs that have become blockbusters because of their weight-loss effects. But the GLP-1s on the market now are expensive, must be kept refrigerated and must be injected. A pill that produces similar results has the potential to become far more widely used, though it is also expected to be expensive.   Lilly said it would seek approval from the Food and Drug Administration later this year to market orforglipron for obesity and early in 2026 for diabetes. https://www.nytimes.com/2025/04/17/health/pill-glp-1-eli-lilly.html XX Use of diabetes technology has dramatically increased and glycemic control has improved among people with type 1 diabetes (T1D) in the US over the past 15 years, but at the same time, overall achievement of an A1c level < 7% remains low and socioeconomic and racial disparities have widened. These findings came from an analysis of national electronic health records of nearly 200,000 children and adults with T1D by Michael Fang, PhD, of the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, and colleagues. The study was published online on August 11, 2025, in JAMA Network Open. Use of continuous glucose monitors (CGMs) increased substantially from 2009-2011 to 2021-2023, from less than 5% in both children and adults to more than 80% and over half, respectively. While A1c levels did drop over the 15 years, just 1 in 5 children and slightly over a quarter of adults achieved a level < 7%. The average A1c level stayed above 8%, with ethnic minorities and low-income patients seeing the smallest gains.       https://www.medscape.com/viewarticle/diabetes-tech-use-rise-a1c-reductions-still-lag-2025a1000lc9 XX Inflammation may predict how well people with diabetes respond to depression treatment, and the effects differ dramatically between type 1 and type 2 diabetes. Diabetes and depression often appear together. Indeed, depression is more than three times more prevalent in people with type 1 diabetes (T1D) and nearly twice as prevalent in people with type 2 diabetes (T2D). When they appear together, treatment for depression can vary widely. In a new study, researchers from the German Diabetes Center (DDZ), the Research Institute of the Diabetes Academy Mergentheim (FIDAM), and the German Center for Diabetes Research (DZD) investigated how inflammation in the body relates to improvement in depression symptoms in people with T1D and T2D. The researchers combined data from three previous German randomized clinical trials that aimed to reduce elevated depressive symptoms and diabetes distress in people with type 1 or type 2 diabetes. Diabetes distress is characterized by feelings of overwhelm, frustration, guilt and worry about diabetes management and its potential complications. A total of 332 participants with T1D and 189 with T2D who had completed both a baseline and 12-month follow-up examination were included in the present study. Measures included depression using the Center for Epidemiological Studies Depression scale (CES-D), blood tests for 76 inflammatory biomarkers, and symptoms broken down into cognitive-affective (e.g., feeling hopeless), somatic (e.g., poor sleep, fatigue), and anhedonia (loss of pleasure) clusters.   After adjusting for factors like age, body mass index (BMI), diabetes duration, cholesterol, and co-existing illnesses, the researchers found that in patients with T1D, higher baseline inflammation was linked to smaller improvements in depression. Inflammation seemed to be more connected to physical/somatic symptoms in T1D patients. In those with T2D, higher baseline inflammation was linked to greater improvements in depression. For these patients, the effect was strongest for cognitive-affective and anhedonia – so, emotional and motivational – symptoms.   The researchers weren't sure what caused the difference between T1D and T2D, but they suggest it might be due to the different forms of immune activation seen in each condition. That is, autoimmune processes in type 1 and metabolic inflammation in type 2. https://newatlas.com/health-wellbeing/inflammation-diabetes-depression-treatment/ XX Parents of children diagnosed with type 1 diabetes suffer an income drop in the years following the diagnosis. The impact is more pronounced in mothers, especially mothers of children diagnosed in preschool years. And these findings come from a European study.. not the US. Previous research has shown that parents of children with type 1 diabetes are at increased risk of stress-related symptoms and may need to reduce their working hours. "In our study, we observed reduced parental work-related incomes in the years following the child's type 1 diabetes diagnosis. The drop was larger in mothers than in fathers. Since mothers earned significantly less than fathers in absolute terms, even before the child fell ill, the relative drop in mothers was 6.6% the year following diagnosis compared to 1.5% in fathers. We further note the greatest impact on work-related incomes in mothers of children diagnosed at preschool age," says Beatrice Kennedy, physician at the Endocrine and Diabetes unit at Uppsala University Hospital and Associate Professor of Medical Epidemiology at Uppsala University, who led the study. This is a huge study, builds on data from national population and health registers and the Swedish Child Diabetes Register (Swediabkids). The study includes the parents of more than 13,000 children diagnosed with type 1 diabetes in Sweden in 1993−2014, as well as more than half a million parents in the general population who have children not diagnosed with diabetes.   The researchers observed that the maternal pension-qualifying incomes (a composite outcome including work-related income and societal benefits) initially increased after the child's diagnosis. This was attributable to mothers applying for the parental care allowance from the Swedish Social Insurance Agency. The parental care allowance was intended to compensate for disease-related loss of work-related income and contribute toward disease-specific costs.   When the research team investigated long-term effects in mothers, they found that the pension-qualifying incomes gradually decreased after eight years, and had not recovered by the end of follow-up − 17 years after the children were diagnosed. https://www.news-medical.net/news/20250811/Mothers-face-greater-financial-impact-following-childe28099s-type-1-diabetes-diagnosis.aspx XX The U.S. Department of Justice has reached a settlement with Metro Nashville Public Schools after allegations that the district violated the Americans with Disabilities Act.   The parents of a student at the Ross Early Learning Center requested that the school monitor their child's glucose monitor. Investigators found the school refused to do so, despite the child's Type 1 Diabetes diagnosis.   As part of the settlement, MNPS agreed to change its policies to allow the use of these devices, ensure trained staff can monitor them throughout the entire school day and at school activities, and improve communication with parents. https://www.wsmv.com/2025/08/12/metro-nashville-public-schools-settles-allegations-it-discriminated-against-students-with-diabetes/ XX Modular Medical has unveiled Pivot, its next-generation insulin patch pump technology aimed at simplifying diabetes care. The company announced its new pump for “almost-pumpers” at the Association of Diabetes Care & Education Specialists (“ADCES”) Conference in Phoenix, Arizona this weekend. It aims for Pivot to target adults with a user-friendly, affordable design.   Modular Medical's current pump, the MODD1, won FDA clearance nearly a year ago. It features new microfluidics technology to allow for the low-cost pumping of insulin. The system has a reservoir size of 300 units/3mL. Users can monitor the pump activity with their cell phone and do not require an external controller. The pump uses a provided, single-use, disposable battery.   The company announced recently that it validated its insulin pump cartridge line for human-use production in the U.S. Days later, it reported the first human use of the MODD1 pump.   Now, it has taken the next steps with the debut of a next-gen pump, set for FDA submission in October.   Modular Medical also gamifies diabetes care The company also said ADCES is the place where it will showcase the first playable level of its new Pivot pump gamified trainin module. Level Ex, a developer of medical games, develops the module.   Modular Medical said gamification offers a way to make medical training more effective and efficient while improving information retention. Given the complexity in pump uptake, the company hopes to provide an easy way to bring its technology to clinicians and patients.   The company expects to have training modules available at the same time as the pump's planned launch in 2026.   “Level One is free because diabetes mastery shouldn't come with a price tag,” Sam Glassenberg, CEO of Level Ex, said. “Modular Medical is breaking barriers too – bringing pump therapy to more people through smart, accessible design. Together, we intend to make diabetes management simpler and more inclusive.   “People learn best through play – and we believe they want to learn about insulin pumps the same way. In Level One, players aren't just mastering diabetes management through gameplay – they're asking to ‘play' with pumps: to explore how they work, understand their benefits, and build confidence before using them in real life. Our partnership with Modular Medical helps make that possible.” https://www.drugdeliverybusiness.com/modular-medical-unveils-next-gen-insulin-pump/ XX On Tuesday, 12 August 2025, Tandem Diabetes Care (NASDAQ:TNDM) presented at the Canaccord Genuity's 45th Annual Growth Conference, outlining strategic shifts and market focus. The company highlighted its plans for commercial transformation in the U.S. and expansion in international markets, alongside addressing competitive challenges and regulatory impacts. While optimistic about growth in Outside the U.S. (OUS) markets, Tandem is navigating a more competitive landscape domestically. We have entered into the pharmacy channel with Mobi only. And so as Mobi's been building up volume, we're getting experience and we're really learning and understanding what pharmacy offers to us. And the proof points have proved out the thesis I said earlier, which is it can really reduce that barrier for patients, is the out of pocket cost. And so we've decided to accelerate our strategy and where we were starting just with Mobi, we are now moving t slim supplies into the pharmacy channel, and that will kick into gear in the fourth quarter. So as people are looking at the cadence of sales for the remainder of the year with this reframing, many folks are seeing what looks like a a might be an outsized fourth quarter and and having trouble understanding those dynamics. We'll be adding the tSIM supplies to those contracts. We also have more coverage. We will have it in the coming weeks effective this year, so we will be increasing that 30% rate before the end of the year. And then, obviously, everyone's in the same cycle right now already negotiating and discussing their 2026 coverage. And so 30% is the floor.   We do expect to continue to grow that coverage in the coming years, and ultimately have a much broader access. Absolutely. It's an exciting technology that allows for us to have an infusion set that extends the wear time from three days to up to seven days. So we're able to use that as part of an independent infusion set, which would then be used with the t slim and with the mobi pump today. But we're also using that same technology as part of the site that's used for mobi when you use it with a tubeless cartridge. So next year, we will launch Mobi in a patch configuration.   It uses the same pump that's available today, but by using a modified cartridge, you're able to wear it as a patch pump. So one of the things we announced on the call is that we're using this extended wear technology as part of that site. So what it allows you to do is to change the portion that you wear in your skin separate from the timing of when you change the insulin cartridge. So it allows for that extended wear time, reduction of burden to the patient, which is especially important for higher volume insulin users as we expand into type two. So from here, we will launch the extended wear site next year along with we'll do a separate regulatory filing for the cartridge portion for Mobi that includes this extended wear technology as a predicate device. So that's another filing that we'll need to do, but we have the clearance today for the independent infusion set, but we'll file another five ten k for use of the extended wear technology as part of the tubeless Mobi feature. https://za.investing.com/news/transcripts/tandem-diabetes-at-canaccord-conference-strategic-shifts-and-market-focus-93CH-3834464 XX MannKind today announced a significant regulatory submission and a large financing agreement with Blackstone. The company submitted its lead inhaled insulin product for expanded FDA approval and secured $500 million in funding, it said.   First, the Danbury, Connecticut-based company announced that it submitted a supplemental Biologics License Application (sBLA) for Afrezza, its inhaled insulin product, in the pediatric population.   MannKind Director of Medical and Scientific Engagement Joanne Rinker, MS, RDN, BC-ADM, CDCES, LDN, FADCES, told Drug Delivery Business News at ADA 2025 that a submission was on the way for children and adolescents aged 4-17 years old. Further data shared at ADA found Afrezza both safe and effective in that age range.   Afrezza is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical inhaler device to slowly bring powder into the lung. A small compartment opens for the insertion of the insulin cartridge, then the user closes it. The only other component is a mouthpiece for the sake of cleanliness. Then, the inhalation takes just two seconds. It requires no electronics or extra components.   The company expects a review acceptance decision early in the fourth quarter of 2025.   “The submission of our supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients is a meaningful milestone for MannKind and people living with diabetes,” said Michael Castagna, CEO of MannKind Corporation.   Additional funding provides a significant boost for MannKind MannKind also announced a strategic financing agreement with funds managed by Blackstone worth up to $500 million. The financing provides MannKind with non-dilutive capital to advance its short- and long-term growth strategies.   This senior secured credit facility includes a $75 million initial term loan funded at closing. It then has a $125 million delayed draw term loan available for the next 24 months. Finally, it features an additional $300 million uncommitted delayed draw term loan available at the mutual consent of MannKind and Blackstone.   The facility bears interest at a calculated SOFR variable rate plus 4.75% and matures in August 2030.   “This strategic financing significantly increases our operating flexibility and provides us substantial access to non-dilutive capital on favorable terms, complementing our strong cash position,” said Castagna. “The funding will support the expansion of our commercial team in preparation for the anticipated launch of the pediatric indication for Afrezza, if approved, continued pipeline advancement, potential business development opportunities, and general corporate purposes. Partnering with the Blackstone team on this transaction positions us to accelerate our next phase of growth and innovation.” https://www.drugdeliverybusiness.com/mannkind-fda-submission-pediatrics-500m-blackstone/ XX   Medtronic MiniMed Abbott Instinct Sensor [Image from Medtronic Diabetes on LinkedIn] The Medtronic Diabetes business today took to social media to share an early preview of a new integrated Abbott sensor for its insulin delivery systems. Medtronic Diabetes — soon to be MiniMed after its planned separation from the medtech giant – said in the post that the new sensor specifically designed for its own systems is called “Instinct.”   “Get a sneak peek at what's coming next: the Instinct sensor,” the business unit's account wrote. “Made by Abbott, the Instinct sensor is designed exclusively for MiniMed systems. We'll share more details about the Instinct sensor when it's commercially available.”   The sensor, built on the Abbott FreeStyle Libre platform, reflects “the power of the partnership,” Abbott EVP, Diabetes Care, Chris Scoggins, told Drug Delivery Business News earlier this year.   Medtronic and Abbott — two of the largest diabetes tech companies in the world — announced a year ago that they entered into a global partnership pairing Abbott continuous glucose monitors (CGMs) with Medtronic insulin delivery systems.   The partnership aims to collaborate on a system based on Abbott's FreeStyle Libre CGMs with Medtronic's automated insulin delivery technology (the latest generation being the MiniMed 780G) and smart insulin pen systems, such as the InPen system.   Read more about Medtronic, Abbott and the rest of the diabetes tech industry in our free Diabetes Technology Special Report. Medtronic's systems previously used its own CGMs, such as the Guardian 4 and the Simplera platform, and the company intends to continue using those systems as part of a comprehensive CGM portfolio. Under the companies' agreement, the systems would be sold exclusively by Medtronic — including the Abbott CGM.   The companies brought the partnership a step further in April when Medtronic announced the submission of an interoperable pump with the Abbott sensor technology to the FDA. They plan to share more details following the expected FDA clearance, which remains pending.   Management also recently emphasized the multi-year nature of the partnership, meaning Medtronic could pair current and future pumps with other Abbott sensors in the future. That could hint at integration with the company's future dual glucose-ketone monitor, as a number of pump makers have already announced collaborations to pair their systems with the sensor once it hits the market. https://www.drugdeliverybusiness.com/medtronic-diabetes-previews-abbott-sensor-minimed/ XX Governor Glenn Youngkin joined Civica officials at the company's Petersburg manufacturing facility to announce a $3 million grant from the Commonwealth of Virginia to accelerate Civica's efforts to develop and produce affordable insulin for Americans living with diabetes.   CivicaRx Logo   "We are proud to partner with Civica in their mission to make essential medicines more accessible," said Governor Youngkin. "This investment reflects our belief in the power of public-private collaboration to improve lives and strengthen communities."   These funds will support the production of insulin aspart, a rapid-acting human insulin analog used to regulate blood sugar in adults and children with diabetes. Civica plans to produce both rapid- and long-acting insulins at its state-of-the-art manufacturing facility in Petersburg, Va., where the company now employs more than 200 skilled workers.1 Over 8 million people living with diabetes need rapid-acting and/or long-acting insulin.   The Governor also announced that he had officially proclaimed August 7 – 14 2025 'Life Sciences Week' demonstrating the Commonwealth's commitment to "accelerating the advancement of the life sciences through public-private partnerships, STEM education, workforce development, and sustained investment in research and development."   "We are grateful for the Commonwealth's support," said Ned McCoy, Civica's President and CEO. "This funding will help us move closer toward our goal of ensuring that no one has to choose between insulin and other basic needs."   Civica and Virginia officials were joined by Lynn Starr, Chief Global Advocacy Officer of Breakthrough T1D, the leading global type 1 diabetes research and advocacy organization.   "More than one million American adults live with type 1 diabetes, and many still, sadly, ration their insulin, due to the prohibitively high cost of this necessary medication," said Starr.  "Civica's work will help to make insulin more affordable for people across the country."   Breakthrough T1D is among more than two dozen organizations and philanthropists, along with the states of Virginia and California, that have partnered with Civica to support the development of affordable insulins.   Civica's insulin initiative aims to provide patients with predictable, transparent pricing — no more than $30 per vial or $55 for a box of five pens — regardless of insurance status.   About Civica Civica is a nonprofit pharmaceutical company established to address drug shortages. It was founded by a group of U.S. health systems and philanthropies who, after more than a decade of chronic shortages, recognized that the market was not self-correcting and that a different approach is required. Civica works to deliver a safe, stable, and affordable supply of essential medicines to U.S. patients.   Media Contact: Liz Power liz.power@civicarx.org +1 860 501 3849 https://cbs4indy.com/business/press-releases/cision/20250807NY46213/governor-glenn-youngkin-announces-3-million-grant-to-support-civicas-affordable-insulin-programs/ XX If you or someone you love is living with diabetes, you already know the fight isn't just medical—it's financial, too. Between daily supplies, doctor visits, and long-term care, the cost of managing type 1 or type 2 diabetes can be overwhelming. Add college or trade school into the equation, and suddenly staying healthy competes with building a future. That's where scholarships for students with diabetes—like Beyond Scholars and others listed here—step in.   Whether you're headed to a university, a two-year college, or a hands-on trade program, these opportunities were created to ease the load.   Scholarships for students with diabetes Beyond Scholars (from Beyond Type 1): $10,000 for recently graduated high school seniors with type 1 diabetes or type 2 diabetes entering college or trade school. This is one of the largest needs-based diabetes scholarships in the United States. This year, awardees will also receive 6 months of wellness coaching through Risely Health.   Applications open: July 25, 2025 Deadline: August 29, 2025 Winners announced: October 2025 https://beyondtype1.org/beyond-scholars-diabetes-scholarships-college-trade-school/ XX Nick Jonas and Kyle Rudolph are using their platforms for a good cause.   On Tuesday, Aug. 12, the singer and the former NFL tight end (via his professional fundraising platform Alltroo) announced they're teaming up to launch a rally featuring a fan-coveted prize: a custom 2025 Volkswagen ID. Buzz electric bus that the Jonas Brothers have brought along for their 20th anniversary tour.   “Ten years ago, we hit the road with a goal to change what it means to live with diabetes. Since then, Beyond Type 1 has grown into the world's largest digital diabetes community, offering the tools, education, and peer support needed to not only survive but thrive with diabetes,” Jonas, who co-founded Beyond Type 1 (a nonprofit that advocates for those living with diabetes), says in a statement.     “We've challenged stigma, built community, provided life-saving resources, and collectively driven global innovation toward prevention and cure. This milestone is a moment to rally even more support for our mission, and partnering with Alltroo helps us do that in a powerful, engaging way.”   Related Stories Nick Jonas on Managing His Diabetes: 'The Mental and Emotional Health Aspect Is Really Important' nick jonas Nick Jonas Says He Was Diagnosed with Diabetes After Joe Told Their Parents: 'Something's Really Wrong' Joe Jonas and Nick Jonas attend the amfAR Cannes Gala 30th edition at Hotel du Cap-Eden-Roc on May 23, 2024 For Rudolph, the campaign is about "celebrating Beyond Type 1's incredible work over the past decade, and standing behind their vision of a world where everyone with diabetes — or at risk of it — has access to the knowledge, care and support needed for early diagnosis and lifelong health."   While the rally is live on Alltroo.com, fans can also scan QR codes available at all 36 Jonas Brothers concert stops to enter for a chance to win the electric bus. (A winner will be selected on November 14, which is World Diabetes Day.)   Jonas, 32, has long been open about his Type 1 diabetes diagnosis at 13 years old. "I had this kind of wrench thrown into things when I was diagnosed and it took a while to figure out how to count carbs to properly dose for insulin and what things would affect me in different ways," he previously told PEOPLE.   "When I was first diagnosed, I was sitting in the hospital and was scared to death, honestly, while I was learning about how to manage this new thing I was dealing with," Jonas recalled. "It would have been amazing to have someone to look at at that time to say, oh, this is a person living with it and they're following their dreams. They're doing what they want to do with their lives and not letting it slow them down."           https://people.com/nick-jonas-kyle-rudolph-launch-fan-rally-diabetes-awareness-11788684

Elle spent years hiding her diabetes, surviving burnout, and even a coma. Now she's leaning in, healing old wounds, and building community through honesty and connection. Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED  or call 888-721-1514 Tandem Mobi  twiist AID System Free Juicebox Community (non Facebook) Type 1 Diabetes Pro Tips - THE PODCAST Juice Cruise 2026 - Come Sail Away Eversense CGM Medtronic Diabetes Drink AG1.com/Juicebox Touched By Type 1 Take the T1DExchange survey Use code JUICEBOX to save 40% at Cozy Earth  Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. Brown et al. Diabetes Care (2021). Sherr et al. Diabetes Care (2022). Pasquel FJ, et al. JAMA Network Open (2025). Single-arm studies comparing 3 months of Omnipod 5 use to standard therapy in 240 people aged 6-70 years and 80 people aged 2-5.9 years with type 1 diabetes and 305 people aged 18-75 years with type 2 diabetes. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!  

Schau dir das Video auf YouTube an und abonniere den Kanal, um keine neue Folge mehr zu verpassen.ZusammenfassungIn dieser Episode enthüllt Julia Tulipan, warum Eiweiß weit mehr als nur ein Baustein für Muskeln ist – es ist der unterschätzte Schlüssel zu deiner gesamten Gesundheit! Viele von uns leiden unbewusst unter einem Eiweißmangel, der sich in Symptomen wie chronischer Müdigkeit, Heißhungerattacken, schlechtem Schlaf oder Problemen mit Haut und Bindegewebe äußert. Julia räumt mit den gängigen Mythen auf und zeigt, dass ausreichend Protein nicht nur essenziell für Zell- und Gewebereparatur ist, sondern auch für die Produktion wichtiger Enzyme, Hormone und Antikörper, die dein Immunsystem stärken.Erfahre, wie Protein als der sättigendste Makronährstoff wirkt und dir dabei hilft, deine Gesamtkalorienzufuhr natürlich zu regulieren. Julia erklärt den "spezifischen Aminosäurehunger" und warum dein Körper bei einem Eiweißmangel ständig nach mehr Nahrung verlangt – oft in Form von ungesunden Cravings. Du lernst, wie du deinen individuellen Proteinbedarf ganz einfach berechnest (mind. 1,6g pro kg Körpergewicht) und welche Mindestmengen für Frauen und Männer gelten, um von den vollen Vorteilen zu profitieren.Ist zu viel Eiweiß schädlich? Julia beleuchtet die aktuelle Forschung und gibt Entwarnung für nierengesunde Erwachsene: Ein "zu viel" gibt es nicht! Zudem spricht sie über die Herausforderungen, den Proteinbedarf rein pflanzlich zu decken, und welche Warnsignale auf einen Mangel hindeuten, inklusive des wichtigen Blutwerts "Gesamteiweiß". Am Ende gibt Julia einen unkomplizierten Praxistipp an die Hand, wie du deine Eiweißzufuhr im Alltag ganz einfach erhöhen kannst, um schon bald mehr Energie und Wohlbefinden zu erleben. Steigere deine Gesundheit – Schritt für Schritt!Was du in dieser Episode lernst

Clara,' a 45-year-old nurse with LADA, shares her fight for a proper diagnosis after bad info from Kaiser—and how growing up with a T1D sister shaped her journey. Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED  or call 888-721-1514 Tandem Mobi  twiist AID System Free Juicebox Community (non Facebook) Eversense CGM Medtronic Diabetes Drink AG1.com/Juicebox Touched By Type 1 Take the T1DExchange survey Use code JUICEBOX to save 40% at Cozy Earth  Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. Brown et al. Diabetes Care (2021). Sherr et al. Diabetes Care (2022). Pasquel FJ, et al. JAMA Network Open (2025). Single-arm studies comparing 3 months of Omnipod 5 use to standard therapy in 240 people aged 6-70 years and 80 people aged 2-5.9 years with type 1 diabetes and 305 people aged 18-75 years with type 2 diabetes. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!  

Approximately 9% of Missourians say they have significant medical bills they can't pay. In the St. Louis region, physicians groups have filed hundreds of lawsuits to collect unpaid debt. New research in the open-access journal JAMA Network Open found groups sued those in zip codes with low-income and Black residents more.

Scott and Erika discuss fear of hypoglycemia. Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED  or call 888-721-1514 Tandem Mobi  twiist AID System Free Juicebox Community (non Facebook) Eversense CGM Medtronic Diabetes Drink AG1.com/Juicebox Touched By Type 1 Take the T1DExchange survey Use code JUICEBOX to save 40% at Cozy Earth  Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. Brown et al. Diabetes Care (2021). Sherr et al. Diabetes Care (2022). Pasquel FJ, et al. JAMA Network Open (2025). Single-arm studies comparing 3 months of Omnipod 5 use to standard therapy in 240 people aged 6-70 years and 80 people aged 2-5.9 years with type 1 diabetes and 305 people aged 18-75 years with type 2 diabetes. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!  

Erin, 49, shares her daughter's T1D diagnosis, twin dynamics, donor pregnancy, and the emotional weight of parenting through it all. Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED  or call 888-721-1514 Tandem Mobi  twiist AID System Free Juicebox Community (non Facebook) Eversense CGM Medtronic Diabetes Drink AG1.com/Juicebox Touched By Type 1 Take the T1DExchange survey Use code JUICEBOX to save 40% at Cozy Earth  Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. Brown et al. Diabetes Care (2021). Sherr et al. Diabetes Care (2022). Pasquel FJ, et al. JAMA Network Open (2025). Single-arm studies comparing 3 months of Omnipod 5 use to standard therapy in 240 people aged 6-70 years and 80 people aged 2-5.9 years with type 1 diabetes and 305 people aged 18-75 years with type 2 diabetes. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!  

A type 1 diagnosis impacts eveyone and everthing. Erika Forsyth is here to discuss. Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED  or call 888-721-1514 Tandem Mobi  twiist AID System Free Juicebox Community (non Facebook) Eversense CGM Medtronic Diabetes Drink AG1.com/Juicebox Touched By Type 1 Take the T1DExchange survey Use code JUICEBOX to save 40% at Cozy Earth  Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. Brown et al. Diabetes Care (2021). Sherr et al. Diabetes Care (2022). Pasquel FJ, et al. JAMA Network Open (2025). Single-arm studies comparing 3 months of Omnipod 5 use to standard therapy in 240 people aged 6-70 years and 80 people aged 2-5.9 years with type 1 diabetes and 305 people aged 18-75 years with type 2 diabetes. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!  

Breaking the Cycle — Robert Steps Up for His Family Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED  or call 888-721-1514 Tandem Mobi  twiist AID System Free Juicebox Community (non Facebook) Eversense CGM Medtronic Diabetes Drink AG1.com/Juicebox Touched By Type 1 Take the T1DExchange survey Use code JUICEBOX to save 40% at Cozy Earth  Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. Brown et al. Diabetes Care (2021). Sherr et al. Diabetes Care (2022). Pasquel FJ, et al. JAMA Network Open (2025). Single-arm studies comparing 3 months of Omnipod 5 use to standard therapy in 240 people aged 6-70 years and 80 people aged 2-5.9 years with type 1 diabetes and 305 people aged 18-75 years with type 2 diabetes. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!  

June Lunney famously characterized the end of life functional course of people with dementia as a slow dwindle over time. Tom Gill later found that people with dementia do indeed have persistent severe disability throughout the last year of their lives. But from our clinical work, many of us are familiar with people with dementia who experience sudden shocks to their health, think hip fracture, think hospitalization for pneumonia.  Those disruptive events or shocks often portend a major decline in function from which people with dementia never fully recover.  And they're often a sign of (or cause of?) worsening prognosis. Today we talk about disruptive events, or health and wealth shocks.  We start with Lauren Hunt, who described the incidence and outcomes of hip fracture and hospitalization for pneumonia in a pair of publications in JAGS, comparing people with dementia who experience these events to people without dementia.  We then turn to social events, starting with Rebecca Rodin, who studied the effect of widowhood on mortality and function for people with dementia, cancer, and organ failure, published in JAMA Network Open.  Finally, we turn to Tsai-Chin Cho, who studied the impact of a wealth shock (loss of 75%+ of wealth in a short time period) on cognitive decline in 4 countries.  Tsai-Chin's article, published in Lancet Healthy Longevity, found a tantalizing hint that countries with stronger safety nets had lower incidence of wealth shocks, and less of a deleterious impact of the wealth shock on cognitive function. Wait, so one key message is that social health is linked to physical and cognitive health?!?  And the government can do something about that?!? Yes indeed, we like to hammer that home regularly, dear listeners. And I enjoyed singing Leonard Cohent's Who By Fire, about the many ways people might die…you know…typical uplifting GeriPal song lyrics! -Alex Smith   Additional links mentioned by Tsai-Chin Cho: -Wealth shocks and mortality in the US -Change in marital status as a risk for wealth shock  

Jenna's journey from burnout to educator shows how one nurse, one moment, can change everything about living with diabetes. Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED  or call 888-721-1514 Tandem Mobi  twiist AID System Free Juicebox Community (non Facebook) Eversense CGM Medtronic Diabetes Drink AG1.com/Juicebox Touched By Type 1 Take the T1DExchange survey Use code JUICEBOX to save 40% at Cozy Earth  Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. Brown et al. Diabetes Care (2021). Sherr et al. Diabetes Care (2022). Pasquel FJ, et al. JAMA Network Open (2025). Single-arm studies comparing 3 months of Omnipod 5 use to standard therapy in 240 people aged 6-70 years and 80 people aged 2-5.9 years with type 1 diabetes and 305 people aged 18-75 years with type 2 diabetes. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!  

Uno studio pubblicato su JAMA Network Open, condotto su oltre mezzo milione di persone nel Regno Unito, ha evidenziato che spostarsi abitualmente in bicicletta può ridurre il rischio di sviluppare forme di demenza. La ricerca ha messo in luce come le abitudini quotidiane di movimento abbiano un impatto diretto sulla salute cognitiva, sottolineando ancora una volta quanto il nostro stile di vita sia legato al benessere, anche mentale. Una pedalata, dunque, può essere un gesto semplice ma prezioso per la nostra mente. A Obiettivo Salute il commento del Prof. Alessandro Padovani, presidente della Società Italiana di Neurologia e direttore della clinica neurologica dell’Università di Brescia.

Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED  or call 888-721-1514 Tandem Mobi  twiist AID System Free Juicebox Community (non Facebook) Eversense CGM Medtronic Diabetes Drink AG1.com/Juicebox Touched By Type 1 Take the T1DExchange survey Use code JUICEBOX to save 40% at Cozy Earth  Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. Brown et al. Diabetes Care (2021). Sherr et al. Diabetes Care (2022). Pasquel FJ, et al. JAMA Network Open (2025). Single-arm studies comparing 3 months of Omnipod 5 use to standard therapy in 240 people aged 6-70 years and 80 people aged 2-5.9 years with type 1 diabetes and 305 people aged 18-75 years with type 2 diabetes. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!  

A Chinese trial found dapagliflozin improved MASH outcomes, with higher resolution and fibrosis improvement rates than placebo. A JAMA Network Open survey showed 42% of abortion providers in ban states relocated, mostly to states with protections, highlighting growing care gaps. An oncology study found AI analysis of body composition better predicted chemo dose reductions than body surface area, especially in women.

Die Themen in den Wissensnachrichten: +++ Regelmäßiges Gehen beugt chronischen Rückenschmerzen vor +++ Zahl der Aasfresser sinkt und das ist ein Problem +++ Menschen verwerten Kalorien unterschiedlich +++**********Weiterführende Quellen zu dieser Folge:Volume and Intensity of Walking and Risk of Chronic Low Back Pain, Jama Network Open, 13.06.2025Global decline of apex scavengers threatens human health, PNAS, 16.06.2025Tree ring isotopes reveal an intensification of the hydrological cycle in the Amazon, Communications Earth and Environment, 17.06.2025Methanogenesis associated with altered microbial production of short-chain fatty acids and human-host metabolizable energy, The ISME Journal, 22.05.2025Coffee Consumption and Mortality among United States Adults: A Prospective Cohort Study, The Journal of Nutrition, 12.05.2025Alle Quellen findet ihr hier.**********Ihr könnt uns auch auf diesen Kanälen folgen: TikTok und Instagram .

Une étude publiée en mai 2025 dans la revue JAMA Network Open, menée par le Barrow Neurological Institute et la Mayo Clinic, a révélé une association significative entre la proximité des terrains de golf et un risque accru de développer la maladie de Parkinson.Méthodologie de l'étudeLes chercheurs ont analysé les données de 419 patients atteints de la maladie de Parkinson et de 5 113 témoins appariés, issus du Rochester Epidemiology Project, couvrant une période de 1991 à 2015. Ils ont examiné la distance entre le domicile des participants et les terrains de golf, ainsi que la nature de leur approvisionnement en eau potable.Résultats principauxLes personnes résidant à moins d'un mile (environ 1,6 km) d'un terrain de golf présentaient un risque accru de 126 % de développer la maladie de Parkinson par rapport à celles vivant à plus de six miles.Le risque diminuait progressivement avec l'éloignement du terrain de golf, suggérant une relation dose-réponse.Les individus vivant dans des zones desservies par des systèmes d'eau potable alimentés par des nappes phréatiques situées sous des terrains de golf avaient un risque presque doublé de développer la maladie, comparé à ceux vivant dans des zones sans terrain de golf.Hypothèses explicativesLes terrains de golf sont souvent entretenus avec des quantités importantes de pesticides pour maintenir la qualité des pelouses. Aux États-Unis, l'utilisation de pesticides sur les terrains de golf peut être jusqu'à 15 fois supérieure à celle observée en Europe. Ces substances chimiques peuvent s'infiltrer dans les nappes phréatiques, contaminant ainsi l'eau potable des zones avoisinantes.De plus, certaines zones géologiques, comme celles avec des sols perméables ou des formations karstiques, facilitent la migration des pesticides vers les sources d'eau souterraines.Limites de l'étudeBien que l'étude établisse une association entre la proximité des terrains de golf et un risque accru de maladie de Parkinson, elle ne prouve pas une relation de cause à effet. Les chercheurs n'ont pas mesuré directement les niveaux de pesticides dans l'eau potable ni pris en compte d'autres facteurs environnementaux ou génétiques pouvant influencer le risque.Cette étude souligne l'importance de considérer les facteurs environnementaux, tels que l'utilisation intensive de pesticides sur les terrains de golf, dans l'évaluation des risques de maladies neurodégénératives comme la maladie de Parkinson. Des recherches supplémentaires sont nécessaires pour confirmer ces résultats et élaborer des recommandations de santé publique appropriées. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Max opens up about bipolar disorder, body image, and the partner who supports her through complex mental and physical health battles. Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED  or call 888-721-1514 Tandem Mobi  twiist AID System Free Juicebox Community (non Facebook) Eversense CGM Medtronic Diabetes Drink AG1.com/Juicebox Touched By Type 1 Take the T1DExchange survey Use code JUICEBOX to save 40% at Cozy Earth  Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. Brown et al. Diabetes Care (2021). Sherr et al. Diabetes Care (2022). Pasquel FJ, et al. JAMA Network Open (2025). Single-arm studies comparing 3 months of Omnipod 5 use to standard therapy in 240 people aged 6-70 years and 80 people aged 2-5.9 years with type 1 diabetes and 305 people aged 18-75 years with type 2 diabetes. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!

Healthy Aging Uncovered!  Did you know the U.S. has the largest healthspan-lifespan gap worldwide, with over 12.4 years lost to disease? A shocking study in JAMA Network Open found that globally, people spend an average of 9.6 years burdened by chronic illness—and the U.S. tops the list for the greatest burden.   Join biochemist Phil George and RN Beth George, MSN, as they dive into the science of healthy aging. Discover practical tips to not only live longer but thrive longer. Expand your biological age, not just your years!   Available now on all podcast platforms. Please feel free to email Phil at philgeorge@charter.net with any health/nutrition/exercise questions. https://www.wellnesswave.net/

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-435 Overview: In this episode, we discuss how screen time—from adolescence through adulthood—can disrupt sleep more than we might realize. Hear what the latest research says about topics like blue light and sleep duration, discover practical strategies to sleep smarter in this digital world, and learn how sleep deprivation can impact the health of your patients. Episode resource links: Zhong, C., Masters, M., Donzella, S. M., Diver, W. R., & Patel, A. V. (2025). Electronic Screen Use and Sleep Duration and Timing in Adults. JAMA Network Open, 8(3), e252493-e252493. Liu, Y. (2016). Prevalence of healthy sleep duration among adults—United States, 2014. MMWR. Morbidity and mortality weekly report, 65. Centers for Disease Control and Prevention (CDC). (2017). Announcement: sleep awareness week, April 23–29, 2017. Morb Mortal Wkly Rep (MMWR), 66(15), 411. Chaput, J. P., Dutil, C., Featherstone, R., Ross, R., Giangregorio, L., Saunders, T. J., ... & Carrier, J. (2020). Sleep duration and health in adults: an overview of systematic reviews. Applied Physiology, Nutrition, and Metabolism, 45(10), S218-S231. Hartley, S., Royant-Parola, S., Zayoud, A., Gremy, I., & Matulonga, B. (2022). Do both timing and duration of screen use affect sleep patterns in adolescents?. Plos one, 17(10), e0276226. Salfi, F., Amicucci, G., Corigliano, D., D'Atri, A., Viselli, L., Tempesta, D., & Ferrara, M. (2021). Changes of evening exposure to electronic devices during the COVID-19 lockdown affect the time course of sleep disturbances. Sleep, 44(9), zsab080. He, J. W., Tu, Z. H., Xiao, L., Su, T., & Tang, Y. X. (2020). Effect of restricting bedtime mobile phone use on sleep, arousal, mood, and working memory: a randomized pilot trial. PloS one, 15(2), e0228756. Guest: Mariyan L. Montaque, DNP, FNP-BC   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com   

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-435 Overview: In this episode, we discuss how screen time—from adolescence through adulthood—can disrupt sleep more than we might realize. Hear what the latest research says about topics like blue light and sleep duration, discover practical strategies to sleep smarter in this digital world, and learn how sleep deprivation can impact the health of your patients. Episode resource links: Zhong, C., Masters, M., Donzella, S. M., Diver, W. R., & Patel, A. V. (2025). Electronic Screen Use and Sleep Duration and Timing in Adults. JAMA Network Open, 8(3), e252493-e252493. Liu, Y. (2016). Prevalence of healthy sleep duration among adults—United States, 2014. MMWR. Morbidity and mortality weekly report, 65. Centers for Disease Control and Prevention (CDC). (2017). Announcement: sleep awareness week, April 23–29, 2017. Morb Mortal Wkly Rep (MMWR), 66(15), 411. Chaput, J. P., Dutil, C., Featherstone, R., Ross, R., Giangregorio, L., Saunders, T. J., ... & Carrier, J. (2020). Sleep duration and health in adults: an overview of systematic reviews. Applied Physiology, Nutrition, and Metabolism, 45(10), S218-S231. Hartley, S., Royant-Parola, S., Zayoud, A., Gremy, I., & Matulonga, B. (2022). Do both timing and duration of screen use affect sleep patterns in adolescents?. Plos one, 17(10), e0276226. Salfi, F., Amicucci, G., Corigliano, D., D'Atri, A., Viselli, L., Tempesta, D., & Ferrara, M. (2021). Changes of evening exposure to electronic devices during the COVID-19 lockdown affect the time course of sleep disturbances. Sleep, 44(9), zsab080. He, J. W., Tu, Z. H., Xiao, L., Su, T., & Tang, Y. X. (2020). Effect of restricting bedtime mobile phone use on sleep, arousal, mood, and working memory: a randomized pilot trial. PloS one, 15(2), e0228756. Guest: Mariyan L. Montaque, DNP, FNP-BC   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com   

Real-talk nutrition with Jenny Smith—simple, practical, no-nonsense. Go tubeless with Omnipod 5 or Omnipod DASH * Eversense CGM Tandem Mobi ** twiist AID System Free Juicebox Community (non Facebook) Medtronic Diabetes Drink AG1.com/Juicebox Use code JUICEBOX to save 40% at Cozy Earth  CONTOUR NextGen smart meter and CONTOUR DIABETES app Dexcom G7 Get your supplies from US MED  or call 888-721-1514 Touched By Type 1 Take the T1DExchange survey Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! *The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. Brown et al. Diabetes Care (2021). Sherr et al. Diabetes Care (2022). Pasquel FJ, et al. JAMA Network Open (2025). Single-arm studies comparing 3 months of Omnipod 5 use to standard therapy in 240 people aged 6–70 years and 80 people aged 2–5.9 years with type 1 diabetes and 305 people aged 18–75 years with type 2 diabetes. ** t:slim X2 or Tandem Mobi w/ Control-IQ+ technology (7.9 or newer). RX ONLY. Indicated for patients with type 1 diabetes, 2 years and older. BOXED WARNING:Control-IQ+ technology should not be used by people under age 2, or who use less than 5 units of insulin/day, or who weigh less than 20 lbs. Safety info: tandemdiabetes.com/safetyinfo Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.   

In this episode of the FIT40 podcast, we dive deep into the most important numbers to focus on to get fit and stay fit for life when it comes to lifestyle management. We cover key health metrics like blood work, cardio, and strength standards that can have a profound impact on your overall wellbeing. Discover practical tips to optimize your cholesterol, blood pressure, A1C, and waist circumference - all essential markers for longevity. Plus, learn science-backed exercise guidelines to improve your cardiac health and build functional strength. This comprehensive guide provides the roadmap to take control of your fitness and wellness at 40 and beyond.FIT40 LINKS:Toned In 20 Workouts: https://fit40-online-coaching.kit.com/1f640492ffBook Your Free Nutrition Assessment: https://calendly.com/coachfitzz/assessmentFIT40 Coaching Info & Application: https://fit40coaching.my.canva.site/applicationFIT40 Family Facebook Group: https://www.facebook.com/groups/fit40familyAFFILIATE LINKS:Try Tonal for 30 Days Risk Free: https://tonal.sjv.io/FIT40Get 10% Off The Genius Protein Shot: https://www.geniusshot.com/?ref=BRYAN_FIT40&transaction_id=10214dd14c839e450a4423af7b1f8eCONNECT WITH ME ONLINEFacebook: https://www.facebook.com/bryan.fitzsimmonsInstagram: ⁠⁠⁠⁠https://www.instagram.com/coach_fitzz/⁠⁠⁠⁠Tiktok: ⁠⁠⁠⁠⁠https://www.tiktok.com/@coach_fitzz?is_from_webapp=1&sender_device=pcYoutube: https://www.youtube.com/@bryan_fit40CITATIONSMile Run Standards – Citations & SourcesBlair SN, et al. (1996).Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. JAMA.▸ Demonstrates strong correlation between cardiorespiratory fitness and mortality.American College of Sports Medicine (ACSM)Guidelines for Exercise Testing and Prescription, 10th ed.▸ Provides normative values for VO₂ max and field tests like the 1-mile run.Cooper KH (1968).A means of assessing maximal oxygen intake. Correlation between field and treadmill testing. JAMA.▸ Foundational study introducing the Cooper test and correlating running distance/time to aerobic capacity.10-Mile Bike Standards – Citations & SourcesCooper InstituteThe Cooper Test Manual (Bike variant).▸ Adaptation of the original Cooper test for stationary and road bikes.Kodama S, et al. (2009).Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events. JAMA.Ainsworth BE, et al. (2011).Compendium of Physical Activities: Classification of energy costs of human physical activities.▸ Supports METs estimation for cycling time trials.British Cycling Time Trial Norms▸ Competitive amateur cycling data used for benchmarking 10-mile efforts.Push-Up Standards – Citations & SourcesYang J, et al. (2019).Association Between Push-up Exercise Capacity and Future Cardiovascular Events Among Active Adult Men. JAMA Network Open.▸ Men completing ≥40 push-ups had dramatically lower cardiovascular event risk.ACSM & NSCA Normative DataACSM's Fitness Assessment ManualNSCA's Essentials of Strength Training and Conditioning▸ Provide age- and sex-specific push-up standards.Kraschnewski JL, et al. (2013).Is strength training associated with mortality benefits? Prev Med.Chin-Ups / Inverted Rows – Citations & SourcesRantanen T, et al. (1999).Midlife muscle strength and human longevity up to age 100 years. J Gerontol A Biol Sci Med Sci.▸ Strength and functional movement as predictors of longevity.ACSM Guidelines & NSCA Standards▸ Norms for bodyweight strength tasks including pull-ups and rows.Army Physical Fitness Test (APFT) & USMC Standards▸ Used to create practical strength thresholds for chin-ups by age/sex.Fagan JM, et al. (2020).Maximal upper-body strength and pull-up performance in physically active adults.▸ Correlates pull-up performance with upper body strength and endurance.Reverse Lunge Standards – Citations & SourcesSchoenfeld BJ, et al. (2016).Resistance training volume enhances muscle hypertrophy. J Strength Cond Res.Cook G. (2010).Movement: Functional Movement Systems.▸ Assesses quality and asymmetry in single-leg patterns like lunges.Kraemer WJ & Ratamess NA. (2004).Fundamentals of resistance training: progression and exercise prescription. Med Sci Sports Exerc.ACSM's Position Stand on Resistance Training for Healthy Adults▸ Confirms efficacy and safety of loaded single-leg exercises for aging resilience.Functionally-relevant studies on fall risk and lower-body strengthHughes VA, et al. (2001). Age-related changes in strength and performance. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit bryanfitzsimmon.substack.com

We have covered menopause on this show on various occasions. That's fitting and non-surprising as we are a women's health education podcast! While vaginal dryness and hot flashes get most of the attention in menopause, and they should, less attention often is given to skin changes. Nonetheless, these dermal manifestations of perimenopause and menopause can be just as disturbing to those affected. Estrogen helps skin produce oil and hold onto water, so extremely dry skin during menopause is common. Plus, according to the American Academy of Dermatology, collagen production drops 30% in the first 5 years of menopause and approximately 2% each year for about the next 20 years. Collagen gives skin its plumpness and structure. The direct-to-consumer market is replete with a variety of over-the-counter estrogen containing products, formulated as facial creams, which are meant to fight the battle of skin aging. But is topical estrogen applied to the face effective? What are the data? You'd be surprised to learn that there is published data on this- even level I data. Are there any safety concerns? We will summarize it in this episode. PLUS, as a “two-for one” special, we will also briefly highlight a brand new publication in the journal JAMA Network Open regarding antenatal corticosteroid dose to delivery interval and fetal benefits.

Die Themen in den Wissensnachrichten: +++ Europa muss sich auf mehr extreme Waldbrände einstellen +++ Laufschuh-Dämpfung ist oft schlecht +++ Bestimmte Kohlenhydrate können länger gesundhalten +++**********Weiterführende Quellen zu dieser Folge:Changing Wildfires - Policy Options for a Fire-literate and Fire-adapted Europe, EASAC, 19.05.2025A New Method and Set of Parameters for Evaluating the Cushioning Effect of Shoe Heels, Revealing the Inadvertent Design of Running Shoes, Bioengineering, 28.04.2025Dietary Carbohydrate Intake, Carbohydrate Quality, and Healthy Aging in Women, JAMA Network Open, 16.05.2025Die Geschichte der Kinderkuren und Kindererholungsmaßnahmen in der Bundesrepublik Deutschland zwischen 1945 und 1989, Humboldt-Universität zu Berlin, 15.05.2025Emergent social conventions and collective bias in LLM populations, Science Advances, 14.05.2025Alle Quellen findet ihr hier.**********Ihr könnt uns auch auf diesen Kanälen folgen: TikTok und Instagram .

Oui, et bien plus souvent qu'on ne le croit. On associe souvent les allergies à l'enfance, mais il est tout à fait possible – et même fréquent – de développer des allergies à l'âge adulte, parfois sans antécédent allergique connu.Une allergie, c'est une réaction excessive du système immunitaire face à une substance normalement inoffensive : pollen, poils d'animaux, acariens, aliments, médicaments… Cette réaction résulte d'une sensibilisation préalable, c'est-à-dire d'un contact avec l'allergène qui a « éduqué » le système immunitaire à considérer cette substance comme une menace.Ce phénomène est désormais bien documenté. Une étude publiée en 2019 dans la revue JAMA Network Open a révélé que près de 11 % des adultes américains souffrent d'une allergie alimentaire, et qu'environ la moitié d'entre eux ont développé cette allergie à l'âge adulte. Parmi les allergies apparues tardivement, les plus fréquentes concernent les fruits de mer, le lait, le blé ou les fruits à coque. L'étude souligne que ces réactions ne doivent pas être minimisées, car elles peuvent aller jusqu'au choc anaphylactique.Mais pourquoi cette sensibilisation se produit-elle parfois à 30, 40 ou 50 ans ? Plusieurs hypothèses existent. D'abord, notre environnement joue un rôle clé. Nous sommes de plus en plus exposés à des substances allergènes dans nos logements, notre alimentation ou nos lieux de travail. La pollution de l'air, en particulier les particules fines, semble augmenter la perméabilité des muqueuses respiratoires, favorisant la pénétration des allergènes.Ensuite, le système immunitaire évolue tout au long de la vie. Il peut devenir plus sensible avec le temps, ou au contraire moins efficace à faire la différence entre les substances inoffensives et dangereuses. Des changements hormonaux (comme ceux liés à une grossesse, à la ménopause ou à certaines maladies) peuvent aussi modifier la réponse immunitaire.Les allergies croisées sont aussi à surveiller. Une personne allergique au pollen de bouleau peut, avec le temps, développer une intolérance aux pommes ou aux noisettes, en raison de la similarité des protéines impliquées.Les symptômes ne diffèrent pas de ceux des allergies précoces : éternuements, démangeaisons, urticaire, difficultés respiratoires… Il est donc essentiel de consulter un allergologue pour confirmer le diagnostic grâce à des tests cutanés ou sanguins.En somme, oui, on peut devenir allergique à l'âge adulte. C'est un phénomène en augmentation, à prendre au sérieux et pour lequel il existe aujourd'hui des solutions thérapeutiques efficaces. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Send us a textHave you ever been told that food doesn't make a difference when it comes to endometriosis pain? Well, today's episode is here to flip that script! We'll dive into the latest findings from the largest-ever international survey on diet and endometriosis, sharing hopeful insights that empower you to take charge of your wellness journey.Here's what you'll hear in today's episode:A brand new study involving over 2,500 endometriosis sufferers and what it reveals about dietary changes and symptom reliefDiscussion of the foods most linked to improved painSpecific statistics from the research, showing the real impact dietary shifts can have (including which foods provided the most relief for participants!)Why certain foods can trigger inflammation—and how this may affect your pain, even if you don't have digestive issuesHow gut bacteria and your microbiome fit into the endometriosis puzzle—and what you can eat to support a healthy gutImportant perspective on "elimination diets" vs. nourishing and supporting your body without restrictionReal-life stories about the difference dietary changes can makeActionable steps: how to get started with dietary changes, what to add to your plate, and how to experiment in a way that works for YOULinks mentioned:Ep. 80 The JAMA Network Open article on diet and endometriosis Article on this study in The GuardianIf you're feeling frustrated by "standard advice" and want practical, down-to-earth guidance on easing Endo pain through food, this episode is for you!Tune in, feel empowered, and as always—take what resonates to nourish your unique body. Thanks for listening! Join the upcoming free workshop: The Endo Relief Blueprint Subscribe to The Endo Belly Girl Podcast: Apple | SpotifyConnect w/ Alyssa: Instagram Website Work w/ Alyssa: Free Endo Diet Guide Work with me 1:1 Join the EndoWellness Initiative Learn more about AlyssaDisclaimer: This podcast is for educational purposes only. This may not be the best fit for you and your personal situation. It shall not be construed as medical advice. The information and education provided here is not intended or implied to supplement or replace professional medical treatment, advice, and/or diagnosis. Always check with your own physician or medical professional before trying or implementing any information read here.

Megan Georges, MS; Elizabeth Pino, PhD; and David Wiley of the Boston Medical Center continue their conversation on rehabilitation access disparities for patients with violent injuries, sharing steps that individual clinicians can take to help close gaps. Their findings were recently published in JAMA Network Open. Let us know what you thought of this week's episode on Twitter: @physicianswkly Want to share your medical expertise, research, or unique experience in medicine on the PW podcast? Email us at editorial@physweekly.com! Thanks for listening!

Megan Georges, MS; Elizabeth Pino, PhD; and David Wiley of the Boston Medical Center describe how survivors of community violence face disproportionately high rates of rehab denials compared with patients injured in motor vehicle crashes. Their findings were recently published in JAMA Network Open. Let us know what you thought of this week's episode on Twitter: @physicianswkly Want to share your medical expertise, research, or unique experience in medicine on the PW podcast? Email us at editorial@physweekly.com! Thanks for listening!

I'm joined by board-certified general surgeon Dr. Lee Howard, who walked away from traditional medicine. Why he feels traditional medicine doesn't really help its patients plus we cover what supplements are good for everyone to take, how to navigate allergy season with kids, what the heck the MTHFR gene is, how we should be approaching our kids' health, why were gonna start to hear more and more about creatine, ways we can help the aging process, plus perimenopause and menopause- how to minimize symptoms and recognize when we start to enter that stage. And we cover once and for all what those silly eye twitches are from. Clip 3: Low Testosterone and Alzheimer's RiskMost people think of testosterone as a hormone that just affects sex drive or muscle mass. But the brain is actually one of its biggest targets. A massive 2023 study from the University of Sydney looked at older men and found something shocking: men with low testosterone had a 26% higher risk of developing Alzheimer's disease. And we're not talking about late-stage life—these patterns start decades earlier. Testosterone helps regulate inflammation in the brain, supports memory circuits, and even promotes the growth of new neural connections. When levels drop too low, especially without being noticed, the brain becomes more vulnerable to decline. Here's the kicker: most men never get their levels checked. And if they do, the 'normal range' is often outdated or way too broad. What's normal for a 75-year-old is not what you want at 45. I've had women come in concerned about their partner's mood, irritability, even motivation—and it turns out his testosterone was tanked. If you're in a long-term relationship and your partner is acting like a different person, you're not imagining it. And getting his hormones evaluated might be the missing link to helping him feel like himself again—and preventing cognitive decline down the line.Study source: University of Sydney & Neuroscience Research Australia (2023)https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.1252Clip 5: Gut Health and MoodThere's a direct, two-way communication line between your gut and your brain—and researchers now believe that the gut may play just as much of a role in mental health as the brain itself. A major review from 2024 showed that people with poor gut diversity were significantly more likely to suffer from depression and anxiety, even when diet and lifestyle were controlled. Why? Because 90% of your serotonin is actually made in your gut. If your microbiome is inflamed or out of balance, your body literally has fewer raw materials to make feel-good brain chemicals. On top of that, gut inflammation sends stress signals to your brain—keeping you in a low-level “fight or flight” state, even when nothing's wrong. And if you've ever felt brain fog, irritability, or sadness after a weekend of sugar and alcohol… this is why. What's exciting is how quickly you can make a shift. Just increasing your fiber, adding fermented foods, or taking the right probiotic can make a measurable difference in just a few weeks. This isn't woo. This is the future of psychiatry. And if you've done therapy, made lifestyle changes, but still don't feel right—check your gut. It might be where your healing needs to start.Study source: Review from the Polish Society of Gastroenterology (2024)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811453Clip 8: Hormone Imbalances and MarriageYou'd be shocked how many couples come into my office thinking they have a communication problem—when what they really have is a hormone problem. He's irritable, unmotivated, maybe withdrawing. She's exhausted, anxious, snapping at small things. They think they've grown apart. They think the spark is gone. But when we test their hormones—testosterone, cortisol, DHEA, thyroid—what we find is that their biochemistry is off. And once we start restoring balance, everything shifts. The mood improves. The intimacy returns. The little things don't feel so overwhelming. We now have solid evidence that hormonal health directly impacts emotional regulation, sexual desire, and even empathy. And if both partners are dysregulated, it can feel like the marriage is falling apart—when really, it's just that their physiology is out of sync. This isn't a relationship failure. It's a hormone crisis. And once you name it, you can fix it. I've seen couples on the brink of divorce completely turn things around—because we stopped blaming each other and started healing their bodies.Study source: APA + American Journal of Men's Health (2023–24)https://journals.sagepub.com/doi/10.1177/15579883231166518Clip 11: Whole Milk in Schools Might Actually Be SmarterFor decades, schools have pushed low-fat or skim milk, based on outdated beliefs about fat and weight. But new evidence is flipping that script. A growing body of research now shows that children who drink whole milk are actually less likely to be overweight than those drinking low-fat milk. Why? Because fat makes food more satisfying. It helps with blood sugar regulation and keeps kids fuller longer—so they're less likely to snack on junk later. In 2025, there's increasing pushback from pediatricians and nutrition researchers against the one-size-fits-all low-fat approach. Some school districts are already considering bringing whole milk back, and they're seeing better nutrition outcomes. Whole milk also contains essential nutrients like vitamin D and calcium in more bioavailable forms, especially when paired with fat. It's time we stop fearing fat—especially when the data shows that cutting it hasn't actually reduced childhood obesity. In fact, we may have made things worse. So if your kid likes whole milk, don't feel guilty. It might just be the more nourishing option after all.Study source: Associated Press report (2025)https://apnews.com/article/e4868fdc2dc4e85aeb9375edcd27da49Clip 13: Hormone Fluctuations and Depression in WomenOne of the biggest blind spots in women's health is how powerful hormone fluctuations are—especially on mood. A 2025 study published in Biomedical Reports found that estrogen and progesterone shifts during puberty, pregnancy, postpartum, and perimenopause play a massive role in rates of depression. This isn't just anecdotal. These hormonal changes alter brain chemistry, sensitivity to stress, and even how the body processes trauma. In puberty, many girls who were previously confident begin to struggle with mood and self-esteem—but instead of checking hormones, we tell them to tough it out. In postpartum, we're finally starting to talk about depression more—but the hormonal crash that happens after birth still catches most women off guard. And in perimenopause, where mood swings and anxiety often resurface, women are still too often told it's “just part of aging.” It's not. It's biology. And the good news is, once you understand that hormones are a major player, you can treat the root cause instead of just masking symptoms. Whether it's bioidentical therapy, lifestyle shifts, or targeted nutrients, women deserve to know that their brains and their hormones are on the same team—and that relief is possible.Study source: Biomedical Reports (2025)https://pubmed.ncbi.nlm.nih.gov/40083602Clip 14: Social Media Changes Teen Brain WiringWe now have MRI data showing that the more often a teen checks social media, the more their brain becomes wired for external validation. In a study from UNC Chapel Hill, researchers found that teens who compulsively checked platforms like Instagram or Snapchat showed measurable changes in the brain's reward centers. These areas lit up more intensely over time, meaning their brains were becoming increasingly sensitive to likes, comments, and digital attention. This isn't just about being distracted. It's about a neurological shift in what they find rewarding—and that shift can impact everything from self-worth to emotional regulation. The researchers even found that this pattern predicts increased anxiety and depression, especially in girls. And it makes sense—when your self-esteem is tied to a number on a screen, even a small drop in engagement feels like social rejection. So what can parents do? First, understand that this isn't just 'teen stuff.' This is brain development. Second, set tech boundaries that prioritize boredom, creativity, and real-life interaction. Even a two-week break can reset the system. Social media isn't going away—but we have to teach kids how to use it without letting it rewire them.Study source: UNC-Chapel Hill (2023)https://www.unc.edu/posts/2023/01/03/study-shows-habitual-checking-of-social-media-may-impact-young-adolescents-brain-developmenClip 16: Screen Time and Toddlers' SleepSleep is how toddlers consolidate memory, regulate mood, and grow both physically and neurologically. But more and more research is showing that screen exposure—even if it's 'educational'—can seriously disrupt toddler sleep. A study published in JAMA Pediatrics found that children ages 2 to 5 who used screens within an hour of bedtime had shorter total sleep and more fragmented rest. Blue light delays melatonin production. Fast-paced content overstimulates the nervous system. And passive consumption before bed blunts their natural wind-down process. We think of it as relaxing—but their brains don't. What's worse is that these disruptions don't just affect nighttime. They carry over into the next day—affecting focus, mood, and even immune function. That's why experts now recommend at least 60 minutes of screen-free time before lights out—especially for young kids. Replace it with a bath, a book, a calm routine. These rituals help their circadian rhythm sync naturally. Sleep isn't just a health pillar—it's a developmental requirement. And screens may be the single biggest obstacle we're overlooking.Study source: JAMA Pediatrics (2024)https://jamanetwork.com/journals/jamapediatrics/fullarticle/282519Clip 18: Hormone-Disrupting Chemicals = Global Health RiskA sweeping review by the Endocrine Society in 2024 called endocrine-disrupting chemicals a 'global health threat.' These are substances—often found in plastics, pesticides, cosmetics, and even receipts—that can mimic, block, or interfere with your body's hormones. They've been linked to everything from infertility to obesity to neurological conditions and cancer. And they're everywhere. Prenatal exposure can affect fetal brain development. Chronic exposure is associated with thyroid dysfunction and metabolic syndrome. And it's not about one product—it's about cumulative load. What's scary is how underregulated many of these substances are in the U.S. compared to Europe. But what's hopeful is that you *can* reduce your exposure. Swap plastic for glass. Say no to fragrance. Wash produce well. Choose organic when you can. Each swap reduces total burden. This isn't alarmist. This is modern environmental medicine. And it affects every system in your body.Study source: Endocrine Society Global Consensus Statement (2024)https://www.endocrine.org/news-and-advocacy/news-room/2024/latest-science-shows-endocrine-disrupting-chemicals-in-pose-health-threats-globallyClip 19: Gut-Brain Axis and Mental HealthWe used to think the brain controlled everything. Now we know the gut plays just as big a role—especially in mental health. The gut-brain axis is a communication superhighway that links your microbiome to your nervous system. And studies show that disruptions in gut health are strongly linked to anxiety, depression, and even neurodevelopmental conditions like ADHD. Certain gut bacteria help produce neurotransmitters like serotonin and GABA. Others regulate inflammation, which directly impacts mood. A 2025 review of over 50 studies found that targeted probiotics improved symptoms of depression in many patients—sometimes as effectively as medication. What you eat, how you digest, and what lives in your gut may affect your mind more than your therapist knows. That doesn't mean meds aren't useful—but it means we have to zoom out. If your gut is inflamed, your brain is inflamed. And no amount of mindset work can override a body that's chemically out of balance. Heal the gut. Watch what changes.Study source: PubMed Meta-Review on Gut-Brain Axis (2025)https://pubmed.ncbi.nlm.nih.gov/3963000Perimenopause: Recognizing and Addressing Early SymptomsDid you know that up to 90% of women experience symptoms of perimenopause years before menopause actually begins? Despite that, most women are either dismissed by doctors or told they're too young to be entering that phase. Perimenopause can start as early as your mid-30s, and it's not just hot flashes—it's insomnia, anxiety, irritability, brain fog, and cycle irregularities. A study from Stanford's Center for Lifestyle Medicine in 2025 emphasized that when women are supported with hormone therapy earlier—during perimenopause, not just postmenopause—they report significantly better mental clarity, energy, and quality of life. But here's the problem: most conventional providers aren't trained to spot this transition, and women are left thinking it's just stress, parenting, or age catching up with them. When really, it's hormones shifting. Estradiol begins to fluctuate, progesterone declines, and the nervous system takes the hit. Women deserve to know what's happening inside their bodies—and what they can do about it. Simple steps like tracking symptoms, checking hormone levels through saliva or urine testing, and considering targeted bioidentical support can change everything. This isn't about vanity—it's about function, clarity, and reclaiming your life before things spiral. If you've ever thought, 'I just don't feel like myself anymore,' and your labs came back 'normal,' this is your sign to dig deeper. You're not crazy. You're not weak. You're likely perimenopausal. And you deserve care that actually sees you.Study source: Stanford Lifestyle Medicine (2025)https://longevity.stanford.edu/lifestyle/2025/03/06/menopause-hormone-therapy-is-making-a-comeback-is-it-safe-and-right-for-you/Menopause and Muscle Mass: The Critical Role of Resistance TrainingMuscle loss during and after menopause is one of the most overlooked drivers of weight gain, fatigue, and metabolic decline in women. In fact, women can lose up to 10% of their muscle mass in the first five years post-menopause. That's not just a cosmetic issue—it's a health crisis. Loss of muscle means decreased insulin sensitivity, weaker bones, and lower resting metabolic rate. But the good news? It's reversible. A landmark 2025 study from the University of Exeter showed that menopausal women who engaged in just 12 weeks of resistance training experienced a 21% improvement in lower body flexibility and significant increases in strength and mobility. What's even more promising is that these improvements came from just two to three sessions a week using basic strength exercises. Muscle is your metabolic engine. And during menopause, when estrogen drops, protecting that muscle becomes your superpower. This isn't about getting shredded or spending hours at the gym—it's about lifting enough weight to send your body the message that it's still needed. Because when your body doesn't get that message, it starts letting muscle go. This leads to increased fat gain, inflammation, and risk of chronic disease. If you're entering menopause or already postmenopausal and you're not lifting weights, you're missing one of the most effective, protective tools for your long-term health.Study source: University of Exeter (2025)https://news.exeter.ac.uk/faculty-of-health-and-life-sciences/first-of-its-kind-study-shows-resistance-training-can-improve-physical-function-during-menopause/The Importance of Sexual Activity as We AgeHere's something most people don't expect: research shows that sexual satisfaction actually improves with age. A 2025 study published in Social Psychology revealed that older adults reported higher levels of emotional intimacy, comfort, and fulfillment during sex—especially when partnered with someone long-term. It turns out that fewer distractions, better communication, and reduced self-consciousness all contribute to more satisfying experiences in later years. But biology still plays a role. Hormonal shifts—like lower estrogen or testosterone—can affect desire, arousal, and comfort. The good news? These challenges are highly treatable. We now have non-invasive, low-risk treatments like vaginal DHEA, testosterone therapy, or pelvic floor physical therapy that can radically improve function and satisfaction. And here's the key: sexual health isn't just about sex. It's about cardiovascular health, immune health, sleep, and mood. An active sex life improves oxytocin levels, reduces stress, and strengthens the emotional bond between partners. Unfortunately, a lot of providers still don't ask about it. And many people are too embarrassed to bring it up. But this is a health issue—and you deserve support. So if intimacy has changed, bring it into the conversation. Because aging doesn't have to mean disconnect—it can actually mean rediscovery.Study source: PsyPost (2025)https://www.psypost.org/sexual-satisfactions-link-to-marital-happiness-grows-stronger-with-age/Preventing Alzheimer's and Type 2 Diabetes: Blood Sugar and Brain HealthThere's a reason Alzheimer's is now being called 'Type 3 Diabetes.' A 2024 study published in JAMA Network Open found that people with Type 2 Diabetes who kept their A1C in the target range significantly lowered their risk of developing Alzheimer's disease. In fact, risk was reduced by up to 60%. Why? Because insulin resistance doesn't just affect your pancreas—it affects your brain. High insulin impairs memory centers like the hippocampus, increases inflammation, and accelerates plaque formation. That means your morning bagel and soda aren't just spiking your blood sugar—they may be spiking your dementia risk. The solution isn't extreme dieting. It's metabolic awareness. Simple tools like continuous glucose monitors, strength training, walking after meals, and eliminating ultra-processed carbs can dramatically stabilize blood sugar. Add in sleep and stress management, and you've got a recipe for brain protection. Most people wait until symptoms start. But prevention is where the power is. If you have a family history of Alzheimer's or Type 2 Diabetes, take this seriously. Your future brain is being built right now by the food on your plate.Study source: JAMA Network Open (2024)https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2821878Testosterone and Aging: It's Not Just About Sex DriveMost people hear 'testosterone' and immediately think of sex drive. But this hormone does way more than that. Testosterone plays a critical role in muscle maintenance, bone density, energy, focus, and mood. A 2025 review from the HE Clinics found that testosterone levels in men start declining around age 30—and continue to drop about 1% per year. That might sound gradual, but by your late 40s or 50s, it's enough to cause noticeable issues: brain fog, irritability, fatigue, and loss of motivation. What's even more concerning is that low testosterone has now been linked to a 26% higher risk of developing Alzheimer's. The brain literally needs testosterone to function well. The challenge is, many men go undiagnosed because they don't get tested—or they get told their levels are 'normal for their age.' But 'normal' doesn't mean optimal. And restoring optimal levels, especially with bioidentical therapies under medical supervision, has been shown to improve mood, clarity, libido, and physical performance. This isn't about bodybuilder doses or quick fixes—it's about reversing a gradual decline that's robbing men of their edge. If you or your partner feels like something is off, it's worth investigating. Because aging doesn't have to mean decline. It can mean recalibration.Study source: HE Clinics (2025)https://heclinics.com/testosterone-therapy-in-older-men-recent-findings/Why Functional Medicine Is Gaining Ground Over Conventional CareIf you've ever felt dismissed in a 7-minute doctor's appointment, you're not alone. Traditional primary care is built for volume—not personalization. That's where functional medicine comes in. A 2019 study published in JAMA Network Open found that patients receiving care through a functional medicine model saw a 30% greater improvement in health-related quality of life than those in conventional care. Why? Because functional medicine is built around asking better questions, running more comprehensive labs, and looking for root causes—not just masking symptoms. Instead of saying 'your labs are normal,' we ask, 'are you thriving?' We look at hormones, nutrition, sleep, gut health, toxin exposure, and genetics as pieces of a bigger picture. This approach is proactive—not reactive. It focuses on reversing disease, not just managing it. More and more people are turning to this kind of care because they're tired of feeling unseen. If you've been told everything is fine but you still feel off, functional medicine might be the approach you need. You deserve care that listens longer, digs deeper, and treats the whole you.Study source: JAMA Network Open (2019)https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2753520A word from my sponsors:Quince - Get cozy in Quince's high-quality wardrobe essentials. Go to Quince.com/honest for free shipping on your order and 365-day returns. LMNT - Get your free LMNT Sample Pack with any purchase at drinklmnt.com/HONEST. Ritual - Support a balanced gut microbiome with Ritual's Synbiotic+. Get 25% off your first month at Ritual.com/BEHONEST. Happy Squatting. Primal Kitchen - primalkitchen.com/honest to save 20% off your next order with code HONEST at checkout.Fatty15 - You can get an additional 15% off their 90-day subscription Starter Kit by going to fatty15.com/HONEST and using code HONEST at checkout.Bilt Rewards - Start earning points on rent you're already paying by going to joinbilt.com/HONEST. For more Let's Be Honest, follow along at:@kristincavallari on Instagram@kristincavallari and @dearmedia on TikTokLet's Be Honest with Kristin Cavallari on YouTubeProduced by Dear Media.This episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct, or indirect financial interest in products, or services referred to in this episode.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In a conversation with CancerNetwork®, Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS, discussed the key findings from a study she published in JAMA Network Open, which demonstrated that most patients with inflammatory breast cancer do not receive all available types of guideline-concordant care they are eligible for. Additionally, data showed disparities regarding receipt of modality-specific therapy among patients who were Black, Asian, Hispanic, or other racial minority populations. Based on these findings, Fayanju highlighted potential next steps for mitigating these gaps in care for certain patients with breast cancer. These strategies included revising stringent inclusion criteria for clinical trial enrollment, which may disproportionately exclude racial minority populations who have higher rates of diabetes or other medical conditions. Fayanju also emphasized educating clinicians across different oncology specialties to recognize how different populations present with inflammatory breast cancer and better understand the context in which patients receive treatment. “I hope [the study] makes some people angry…Frustration can be a wonderful fuel,” Fayanju stated regarding her research. “[By] recognizing that there isn't as much guideline-concordant care receipt amongst all people as there should be and the hope that's provided when we achieve concordant care, we can mitigate and eliminate racial disparities. I hope [that] will motivate people to think about how we can get more guideline-concordant care to more people and how we can incorporate diverse populations in the development of guidelines for concordant care at the beginning. Then, how can we also develop treatments that achieve efficacious results across diverse populations?” Fayanju is the Helen O. Dickens Presidential Associate Professor, chief in the Division of Breast Surgery at Penn Medicine, surgical director of Rena Rowan Breast Center, director of Health Equity Innovation at Penn Center for Cancer Care Innovation (PC3I), and senior fellow at Leonard Davis Institute of Health Economics (LDI), Perelman School of Medicine at the University of Pennsylvania. Reference Tadros A, Diskin B, Sevilimedu V, et al. Trends in guideline-concordant care for inflammatory breast cancer. JAMA Netw Open. 2025;8(2):e2454506. doi:10.1001/jamanetworkopen.2024.54506

Send us a textIn this Journal Club episode, Ben and Daphna review several impactful studies shaping neonatal care. They begin with a secondary analysis of the ETTNO trial, which examined whether liberal transfusion thresholds reduce intermittent hypoxemia or improve neurodevelopmental outcomes in extremely low birth weight infants. Despite prior concerns, the study found no benefit to liberal thresholds, supporting current restrictive practices. A JAMA Network Open study follows, revealing that late preterm infants are least likely to receive mother's own milk at 12 weeks, underscoring an overlooked group in breastfeeding support efforts. Dr. David Rube joins the show to discuss a two-year follow-up of the IN-RECSURE trial, which investigated whether lung recruitment before surfactant administration leads to improved long-term outcomes—ultimately showing no difference in death or disability. The hosts also explore a meta-analysis on umbilical cord blood therapy for children with cerebral palsy, highlighting benefits in motor function for younger children with milder CP when treated at higher doses. Additional topics include the association between funisitis and cerebral palsy in extremely preterm infants and the AZTEC trial's conclusion that azithromycin does not reduce BPD. The episode concludes with a review of best practices for discussing autopsy with families in the NICU setting. As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Diabetic retinopathy remains a leading cause of preventable blindness worldwide, and AI may facilitate screening, if such models continue to perform well when they are deployed in the real world. Coauthors Arthur Brant, MD, of Stanford University, and Sunny Virmani, MS, of Google join JAMA+ AI Editor in Chief Roy H. Perlis, MD, MSc, to discuss a new study published in JAMA Network Open. Related Content: Diabetic Retinopathy Is Massively Underscreened—an AI System Could Help Performance of a Deep Learning Diabetic Retinopathy Algorithm in India

Send us a textIn this packed episode of Neo News, Eli, Ben, and Daphna dive into the headlines impacting neonatology and public health. The trio starts with the controversial confirmation of Robert F. Kennedy Jr. as head of HHS, analyzing his actions around the CDC, NIH, vaccine policy, and the implications of promoting “informed consent” messaging in place of public health advocacy. Drawing from reporting by The New York Times, STAT News, and Science Magazine, the team unpacks how these shifts could affect vaccine uptake in the NICU.Next, they examine the threat to birthright citizenship in the U.S., based on analysis from The New York Times, and how immigration policy may directly impact NICU families' access to care and trust in healthcare systems.They also discuss a Wall Street Journal article detailing the erosion of trust in physicians post-pandemic and the fallout from a recent JAMA Pediatrics study on therapeutic hypothermia in late preterms, which raised questions about research transparency.Other highlights include studies from Scientific Reports, JAMA Network Open, and The New York Times on air pollution, paternity leave, language-concordant care, and breastfeeding. The show ends with a call to action from Dr. Shadel Shah's op-ed advocating for the continuation of the PREEMIE Act. As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

durée : 00:01:56 - Le vrai ou faux - Une étude américaine publiée dans la revue médicale Jama Network Open alerte sur la désinformation médicale. Dans son viseur : les publications d'influenceurs qui incitent les internautes à aller se faire tester pour détecter d'éventuelles futures maladies ou cancers, sans alerter sur les conséquences éventuellement nocives.

AI can play a role in addressing language barriers in health care. In a recent Editorial in JAMA Network Open, Pilar Ortega, MD, MGM, of the University of Illinois College of Medicine, and coauthors emphasized the urgent need for integrating language equity into digital health solutions. Dr Ortega joins JAMA and JAMA+ AI Associate Editor Yulin Hswen, ScD, MPH, to discuss. Related Content: Researcher Proposes New Framework for Language Equity in Health Technology Language Equity in Health Technology for Patients With Non–English Language Preference Challenges to Video Visits for Patients With Non–English Language Preference

The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:1. Brain Function Outcomes of Recent and Lifetime Cannabis Use. JAMA Network Open 2025. Discussion by: Guest:Maija Adourian, DOResident– Family Medicine Residency Program Jefferson Health – Abington2. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine. Discussion by:Guest:Christopher M. Kramer, MD George A. Beller/Lantheus Medical Imaging Distinguished Professor of Cardiovascular Medicine Chief of the Cardiovascular Division UVA Health3. Screening for Osteoporosis to Prevent FracturesUS Preventive Services Task Force Recommendation Statement. Discussion by:Guest: Anupriya Grover-Wenk, DOFaculty– Family Medicine Residency ProgramJefferson Health – AbingtonMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. This Podcast Episode does not offer CME/CE Credit. Send us a text about this episode. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

A recent study in JAMA Network Open evaluates the use of machine learning algorithms to assess the management of urinary tract infection (UTI). Author Sanjat Kanjilal, MD, MPH, professor in the Department of Population Medicine at Harvard Medical School and Harvard Pilgrim Healthcare Institute, joins JAMA Associate Editor Yulin Hswen, ScD, MPH, to discuss this topic and more. Related Content: Researchers Use Machine Learning to Put Older Clinical Guidelines to the Test Use of Machine Learning to Assess the Management of Uncomplicated Urinary Tract Infection

Vielleicht hast Du Dir vorgenommen, deinen Körperfettanteil zu senken, vielleicht wünschst Du Dir eine noch knackigere Figur. Oder Du möchtest einfach gesünder und fitter sein, ohne abzunehmen. Prima! Du hast richtig gute Freunde, die dich bei deinem Plan tatkräftig unterstützen können. Wer das sein soll? Na, deine Muskeln! Solange Du bereit bist, wenigstens 60 Minuten pro Woche – also gerade mal die Dauer einer Folge Deiner Lieblingsserie – ins Training zu investieren, sage ich Dir: Wir bekommen das hin. Hier sind die Basics für Dein Training – und wie Du Deine verfügbare Zeit so ins Training investierst, das Du möglichst viel für Dich herausholst. ____________ *WERBUNG: AG1 (by Athletic Greens): Als FMM-Hörer bekommst Du zur ersten Bestellung kostenlos 5 Travelpacks, eine Flasche Vitamin D3+K2 plus das Willkommenspaket mit Shaker und schicker Edelstahldose. ____________ Vielen Dank für Dein Vertrauen. Hier sind ein paar weitere Wege, wie ich Dich unterstützen kann.​ ​Kostenlos: Email: #DRNBLBR Newsletter (jeden Sonntagmorgen) Instagram: @fitnessmitmark​ Ebook: Ratgeber Nahrungsergänzung​ ​Kostenpflichtig: Buch: Dranbleiben! Buch: Looking Good Naked​ ​Workouts: #DRNBLBR Bodyweight Circle​ Persönliche Betreuung: MarathonFitness Online-Coaching​ _____________

Sugar-sweetened beverages, the epidemiology of driving after an ICD, BP measurements, and massive EBM lesson in EVT for acute stroke are the topics John Mandrola, MD, discusses in today's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Sugar-Sweetened Beverages Sugary Drinks Fuel Millions of Diabetes and CVD Cases https://www.medscape.com/viewarticle/sugary-drinks-fuel-millions-diabetes-and-cvd-cases-2025a10002wr Nature Medicin;e Epidemiologic Study https://www.nature.com/articles/s41591-024-03345-4 JAMA-Network Open;  Beverage Tax Observational Study https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2829505 Lancet Regional Health; Beverage Tax Philadelphia EHR 10.1016/j.lana.2024.100906 II. Driving With an ICD JACC Electrophysiology paper https://doi.org/10.1016/j.jacep.2024.12.002 Earlier HEART paper https://heart.bmj.com/content/110/24/1401 III. Blood Pressure Measurements and Simple RCTs BP Readings in Noisy Market as Good as Quiet Office? https://www.medscape.com/viewarticle/bp-readings-noisy-market-good-quiet-office-2025a10002z0 Annals of Internal Medicine Study https://www.acpjournals.org/doi/10.7326/ANNALS-24-00873 IV. A Big Shake-up in Interventional Stroke Care Endovascular Therapy Fails to Show Benefit in Distal Occlusion Stroke  https://www.medscape.com/viewarticle/endovascular-therapy-fails-show-benefit-distal-occlusion-2025a100035u ESCAPE-MeVO https://www.nejm.org/doi/full/10.1056/NEJMoa2411668 DISTAL trial https://www.nejm.org/doi/full/10.1056/NEJMoa2408954 J. Mocco Editorial https://www.nejm.org/doi/full/10.1056/NEJMe2500492 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Digital health technologies, including patient portals, are widely used by older adults, as described in a recent study published in JAMA Network Open. Author Cornelius James, MD, of the University of Michigan joins JAMA+ AI Editor in Chief Roy H. Perlis, MD, MSc, to discuss the study and how it fits with his own experience in the clinic. Related Content: Study Finds Most Older Adults Use Digital Health Technologies, Plus Some Surprises Use of Digital Health Technologies by Older US Adults

What are psychedelics? How do they impact your brain? Are they safe? Parker and Emma unpack the current research and legality of psychedelics and discuss the ethical implications of psychoactive drugs. Sources: Cheung, K., Earp, B. D., Patch, K., & Yaden, D. B. (2025). Distinctive But Not Exceptional: The Risks of Psychedelic Ethical Exceptionalism. The American Journal of Bioethics, 25(1), 16–28. Tiwari, P., Davoudian, P. A., Kapri, D., Vuruputuri, R. M., Karaba, L. A., Sharma, M., … Vaidya, V. A. (2024). Ventral hippocampal parvalbumin interneurons gate the acute anxiolytic action of the serotonergic psychedelic DOI. Neuron, 112(22), 3697-3714. Wang, E., Mathai, D. S., Gukasyan, N., Nayak, S., & Garcia-Romeu, A. (2024). Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. Healthcare Professionals. Scientific Reports, 14(1), 28022. Davis, A. K., Bates, M., Lund, E. M., Sepeda, N. D., Levin, A. W., Armstrong, S. B., … Yehuda, R. (2024). The Epidemiology of Psychedelic Use Among United States Military Veterans. Journal of Psychoactive Drugs, 1–14. Published Online. September 12, 2024. Ehrenkranz, R., Agrawal, M., Nayak, S. M., & Yaden, D. B. (2024). Adverse events should not be surprising in psychedelic research. Psychedelic Medicine. Published Online. September 4, 2024. Hinkle, J. T., Graziosi, M., Nayak, S. M., & Yaden, D. B. (2024). Adverse events in studies of classic psychedelics. JAMA Psychiatry, 81(12), 1225-1235. Yaden, D. B., Goldy, S. P., Weiss, B., & Griffiths, R. R. (2024). Clinically relevant acute subjective effects of psychedelics beyond mystical experience. Nature Reviews Psychology, 3(9), 606–621. Goldy, S. P., Hendricks, P. S., Keltner, D., & Yaden, D. B. (2024). Considering distinct positive emotions in psychedelic science. International Review of Psychiatry, 1–12. Published Online. September 2, 2024. Heller, N. H. & Barrett, F. S. (2024). Teaching a new dog old tricks: bringing rigor, grounding, and specificity to psychedelic neuropsychopharmacology. Neuropsychopharmacology. Published Online. August 26, 2024. Yaden, D. B., Mathai, D., Bogenschutz, M., & Nichols, D. E. (2024). The pharmacology of hallucinogens. In: Miller et al. (Eds.). Principles of Addiction Medicine. American Society of Addiction Medicine. Yaden, D. B., Nayak, S. M., Griffiths, R. R. (2024). Belief change and agnostic frames in psychedelic research and clinical contexts. In: C. Letheby (Ed.). Philosophy and the psychedelic renaissance. Oxford University Press, New York. DiRenzo, D., Barrett, F. S., Perin, J., Darrah, E., Christopher-Stine, L., & Griffiths, R. R. (2024). Impact of psilocybin on peripheral cytokine production. Psychedelic Medicine, 2(2). Cheung, K., Propes, C., Jacobs, E., Earp, B. D., & Yaden, D. B. (2024). Psychedelic group-based integration: Ethical assessment and initial recommendations. International Review of Psychiatry, 1–11. Tiwari, P., Ehrenkranz, R., & Yaden, D. B. (2024). Psychiatric Applications of Psychedelics: Neurobiological Foundations for Treatments of Depression, Anxiety, and Obsessive-Compulsive Disorder. Advances in Psychiatry and Behavioral Health. McGuire, A. L., Cohen, I. G., Sisti, D., Baggott, M., Celidwen, Y., Devenot, N., Gracias, S., Grob, C., Harvey, I., Kious, B., Marks, M., Mithoefer, M., Nielson, E., Öngür, D., Pallas, A., Peterson, A., Schenberg, E. E., Summergrad, P., Waters, B., Williams, M. T., & Yaden, D. B. (2024). Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement. JAMA Network Open, 7(6), e2414650.

How do patients feel about the quality of AI-generated responses to their messages to clinicians? Author Eleni Linos, MD, DrPH, of Stanford joins JAMA+ AI Editor in Chief Roy H. Perlis, MD, MSc, to discuss her recent study in JAMA Network Open that characterized satisfaction with these messages. Related Content: Study Finds People Prefer AI Over Clinician Responses to Questions in the Electronic Medical Record Perspectives on Artificial Intelligence–Generated Responses to Patient Messages

A study in NEJM shows that abelacimab, a fully human monoclonal antibody targeting factor XI, significantly reduces bleeding risk compared to rivaroxaban in atrial fibrillation patients, suggesting a safer alternative for stroke prevention. Data from JAMA Health Forum reveals growing consolidation of primary care practices by hospitals and private equity firms, driving up healthcare costs without clear quality improvements. The largest U.S. tuberculosis outbreak in Kansas underscores the importance of vigilance and rapid response by healthcare providers, while a study in JAMA Network Open finds women, particularly nonmenopausal females aged 40–54, at higher risk for long COVID, emphasizing the need for tailored prevention and treatment strategies.

The burden of responding to clinician inbox messages may be a contributor to burnout. Eden English, MD, of UCHealth joins JAMA+ AI Editor in Chief Roy H. Perlis, MD, MSc, to discuss her recent study published in JAMA Network Open, which examined the use of large language models to reply to patient messages. Related Content: Researchers Tested an AI Tool That Drafts Responses to Patient Messages—Here's What They Found Utility of Artificial Intelligence–Generative Draft Replies to Patient Messages Are Artificial Intelligence–Generated Replies the Answer to the Electronic Health Record Inbox Problem?

American Indian and Alaska Native communities have higher rates of suicide than any other racial or ethnic group in the US. A recent study published in JAMA Network Open describes an AI-based suicide screening tool investigated in an American Indian community. Author Emily Haroz, PhD, of Johns Hopkins Bloomberg School of Public Health, joins JAMA and JAMA+ AI Associate Editor Yulin Hswen, ScD, MPH. Related Content: How AI Could Help Clinicians Identify American Indian Patients at Risk for Suicide Performance of Machine Learning Suicide Risk Models in an American Indian Population

Do remote and hybrid managers need different skills to those who work in-person? If so, what are those skills and how do we develop them?  In this first episode of The Mindtools L&D Podcast for 2025, Ross Dickie and Ross Garner are joined by return guest Gary Cookson, author of Making Hybrid Working Work. We discuss:  The ‘sensory loss' that takes place when managers move to a hybrid environment  The digital signals that help managers understand their teams  Strategies for building hybrid management capability.  Gary's book, Making Hybrid Working Work, is available now from Kogan Page.  During the discussion, we referenced a few other episodes of our podcast:  271 — Jobcraft Country  406 — Revisiting 70:20:10: Theory into practice  407 — Revisiting 70:20:10: From learning to performance  421 — Good managers balance care with results  Ross Garner also discussed ‘context-dependent memory effect'.  In ‘What I Learned This Week', we each shared a paper:  Ross G: Vences, M., Köhler, J., Hutter, C. R., Preick, M., Petzold, A., Rakotoarison, A., ... & Scherz, M. D. (2024). Communicator whistles: A Trek through the taxonomy of the Boophis marojezensis complex reveals seven new, morphologically cryptic treefrogs from Madagascar (Amphibia: Anura: Mantellidae). Vertebrate Zoology, 74, 643-681.  Gary: Veronese, N., Stubbs, B., Noale, M., Solmi, M., Vaona, A., Demurtas, J., ... & Fontana, L. (2017). Fried potato consumption is associated with elevated mortality: an 8-y longitudinal cohort study. The American journal of clinical nutrition, 106(1), 162-167.  Goh, E., Gallo, R., Hom, J., Strong, E., Weng, Y., Kerman, H., ... & Chen, J. H. Large Language Model Influence on Diagnostic Reasoning. JAMA Network Open, 7(10).  For more from us, including details of our new Manager Skill Builder, visit mindtools.com.   There, you'll also find details of our award-winning performance support toolkit, our off-the-shelf e-learning, and our custom work.    For more from Gary, see EpicHR.co.uk  Connect with our speakers     If you'd like to share your thoughts on this episode, connect with us on LinkedIn:  Ross Garner  Ross Dickie  Gary Cookson

How can hospitals use early warning score tools to risk stratify patients without adding to alarm fatigue? Dana Edelson, MD, MS, of the University of Chicago joins JAMA+ AI Editor in Chief Roy H. Perlis, MD, MSc, to discuss a recent study published in JAMA Network Open that she coauthored, comparing 6 early warning scores designed to recognize clinical deterioration in hospitalized patients. Related Content: Researchers Compared Hospital Early Warning Scores for Clinical Deterioration—Here's What They Learned Early Warning Scores With and Without Artificial Intelligence

Chatbots may have a role in enhancing clinical care, but the best way to apply them remains a work in progress. Jonathen Chen, MD, PhD, and Ethan Goh, MD, MS, of Stanford, join JAMA and JAMA+ AI Associate Editor Yulin Hswen, ScD, MPH, to discuss their randomized clinical trial published in JAMA Network Open investigating the use of chatbots in clinical practice. Related Content: An AI Chatbot Outperformed Physicians and Physicians Plus AI in a Trial—What Does That Mean? Large Language Model Influence on Diagnostic Reasoning